Nontuberculous Mycobacterium Treatment Market Size

  • Report ID: 4072
  • Published Date: Aug 16, 2024
  • Report Format: PDF, PPT

Nontuberculous Mycobacterium Treatment Market Size

Nontuberculous Mycobacterium Treatment Market size was valued at USD 9.11 billion in 2023 and is likely to reach USD 12.72 billion by 2036, registering around 2.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of nontuberculous mycobacterium treatment is estimated at USD 9.3 billion. The growth of the market can be attributed to the increasing prevalence of nontuberculous mycobacterial lung disease, especially amongst the elderly population across the globe. Moreover, the rising geriatric population on a global level, is further estimated to boost the market growth. According to the data by the World Bank, 723,484,054 individuals were aged above 64 years of age, as of 2020. Furthermore, the high occurrence of various lung-related issues amongst people are further projected to boost the market growth. As per the data by the National Organization for Rare Disorder, chronic lung infection is the most common complication affecting approximately 94% of individuals. Additionally, increasing health awareness amongst people, government initiatives to provide efficient health facilities, and growing health expenditure are estimated to boost the market growth.


Nontuberculous Mycobacterium Treatment Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4072
  • Published Date: Aug 16, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nontuberculous mycobacterium treatment is estimated at USD 9.3 billion.

Nontuberculous Mycobacterium Treatment Market size was valued at USD 9.11 billion in 2023 and is likely to reach USD 12.72 billion by 2036, registering around 2.6% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of nontuberculous mycobacterium infections will boost the market growth.

Asia Pacific industry is predicted to hold largest revenue share by 2036, on the back of improving healthcare infrastructure, along with growing geriatric population in the region.

The major players in the market are Atara Biotherapeutics, Inc., Kadmon Holdings, Inc., Beyond Air Inc., Savara Inc., RedHill Biopharma Ltd., Insmed Inc., Novartis AG, GlaxoSmithKline plc, and TFF Pharmaceuticals, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample